Australia Health

OncoSil Medical (ASX:OSL) reported a 45.8% year-on-year increase in first-quarter sales revenue following approval from the U.S. Food and Drug Administration for its medical device.

Clinuvel Pharmaceuticals (ASX:CUV) has submitted a marketing authorisation dossier in Europe for NEURACTHEL Instant.

Reece (ASX:REH) delivered first-quarter sales revenue of $2.51 billion, up 4.3% from the same period last year.

ResMed (ASX:RMD) reported first-quarter revenue for fiscal year 2027 grew 6% to US$1.4 billion.

Alcidion Group (ASX:ALC) released a year-to-date trading update showing contracted revenue reached $50 million by late September.

Mesoblast (ASX:MSB) reported a 44% year-on-year increase in first-quarter net revenue from Ryoncil sales, which reached US$28 million for the period.

SciDev (ASX:SDV) has secured three new chemistry supply contracts valued at approximately $8 million across the mining, utilities, and infrastructure sectors.

Oneview Healthcare (ASX:ONE) achieved its strongest quarter for new customer additions after signing six healthcare organisations in the three months to September.

Resonance Health (ASX:RHT) secured $6 million in firm commitments via an oversubscribed share placement.

Arovella Therapeutics (ASX:ALA) has dosed its first patient in the SAPPHIRE phase 1 trial of cell therapy ALA-101.

Dementia, including Alzheimer's disease, caused 19,019 deaths in Australia during 2025, accounting for just over 10% of all national fatalities.

Biopharmaceutical business Immuron (ASX:IMC) generated $2.2 million in unaudited global sales for the quarter ended Sept. 30.